ETFs Genmab A/S

GMAB

DK0010272202

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen Other stock markets 09:50:00 13/02/2026 pm IST			5-day change	1st Jan Change
1,904.50 ^DKK	+1.25%		-2.73%	-6.04%

13/02	Diary - Europe's STOXX 600 Corporate Earnings Week Ahead	RE
21/01	DNB Carnegie Upgrades Genmab to Buy, Raises PT	MT

ETFs positioned on Genmab A/S

Name	Varia. Jan 1.	Weight	AuM
XACT NORDEN (UCITS ETF) - EUR	+3.28%	3.64%	1,387 M€
NOMURA NEXT FUNDS INTERNATIONAL EQUITY MSCI-KOKUSAI (YEN-HEDGED) ETF - JPY	-0.48%	0.75%	26 M€
VANECK WORLD EQUAL WEIGHT SCREENED UCITS ETF - EUR	+3.97%	0.56%	1,212 M€
VANECK MULTI-ASSET GROWTH ALLOCATION UCITS ETF - EUR	+2.79%	0.45%	32 M€
VANECK MULTI-ASSET CONSERVATIVE ALLOCATION UCITS ETF - EUR	+4.25%	0.19%	20 M€
VANGUARD INTERNATIONAL EQUITY INDEX FUNDS - VANGUARD FTSE ALL-WORLD EX-US ETF	+2.80%	0.11%	33,076 M€
LEVERAGE SHARES PLC - 3X LONG TOTAL WORLD ETP	-.--%	0.06%	1 M€
NOMURA NEXT FUNDS INTERNATIONAL EQUITY MSCI-KOKUSAI (UNHEDGED) ETF - JPY	-0.69%	0.04%	399 M€
VANGUARD LIFESTRATEGY 80% EQUITY UCITS ETF ACC - EUR	+1.50%	0.04%	864 M€
VANGUARD LIFESTRATEGY 80% EQUITY UCITS ETF - DISTRIBUTING - EUR	+1.41%	0.03%	64 M€
RAREVIEW SYSTEMATIC EQUITY ETF - USD	+3.96%	0.03%	50 M€

1 2

Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (80.6%); - income from research and development (9.3%); - other (10.1%): primarily income from partnership agreement. At the end of 2024, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase. Net sales are distributed geographically as follows: Denmark (91.9%), the United States (4.2%) and Japan (3.9%).

Employees

2,681

Sector

Biotechnology & Medical Research

Calendar

19/03 - Annual General Meeting

More about the company